DAB2IP attenuates chemoresistance of triple-negative breast cancer through sequestration of RAC1 to prevent β-catenin nuclear accumulation.

Zhenchong Xiong Lin YangNing LiJianchang FuPeng LiuPeng SunWeidong WeiXiaoming Xie

Published in: Clinical and translational medicine (2022)

We revealed that DAB2IP attenuates chemoresistance of TNBC via inhibition of RAC1-mediated β-catenin nuclear accumulation. Decitabine treatment results in re-expression of DAB2IP by inhibiting DNA methylation and could be a potential therapeutic strategy for chemoresistance in TNBC.

Keyphrases

dna methylation
epithelial mesenchymal transition
cell proliferation
poor prognosis
acute myeloid leukemia
cancer stem cells
gene expression
genome wide
signaling pathway
cell migration
single cell
binding protein
copy number
replacement therapy